TY - JOUR
T1 - Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response
AU - Bayliss, Jill
AU - Hilger, Amy
AU - Vishnu, Prakash
AU - Diehl, Kathleen
AU - El-Ashry, Dorraya
PY - 2007/12/1
Y1 - 2007/12/1
N2 - Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα- breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα- tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα- breast cancer cell lines, ERα - breast tumors, and tumor cell cultures obtained from ERα- tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα- breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα- breast cancer cell lines. Treatment of ERα- tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα- tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data showboth the possibility of restoring ERα expression and antiestrogen responses in ERα- breast cancer and suggest that there exist ERα- breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.
AB - Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα- breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα- tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα- breast cancer cell lines, ERα - breast tumors, and tumor cell cultures obtained from ERα- tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα- breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα- breast cancer cell lines. Treatment of ERα- tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα- tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data showboth the possibility of restoring ERα expression and antiestrogen responses in ERα- breast cancer and suggest that there exist ERα- breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.
UR - http://www.scopus.com/inward/record.url?scp=37249069903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37249069903&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-0587
DO - 10.1158/1078-0432.CCR-07-0587
M3 - Article
C2 - 18056179
AN - SCOPUS:37249069903
SN - 1078-0432
VL - 13
SP - 7029
EP - 7036
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 23
ER -